Abstract
This chapter reviews evidence behind the epidemiologic, diagnostic, prognostic, and treatment topics in the more commonly encountered neuromuscular diseases. Clinical questions and evidence-based answers are discussed for amyotrophic lateral sclerosis, diabetic peripheral neuropathy, inclusion body myositis, and myasthenia gravis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sorenson E, Stalker A, Kurland L, Windebank A. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925–1998. Neurology. 2002;59:280–2.
Fang F, Valdimarsdóttir U, Bellocco R, Ronnevi L, Sparén P, Fall K, et al. Amyotrophic lateral sclerosis in Sweden, 1991–2005. Arch Neurol. 2009;66(4):515–9.
Zoccolella S, Beghi E, Palagano G, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008;79:33–7.
Mandrioli J, Faglioni P, Nichelli P, et al. Amyotrophic lateral sclerosis: prognostic indicators of survival. Amyotrophic Lateral Sclerosis. 2006;7:217–26.
Bensimon G, Lacomblez L, Meninger V, et al. A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585–91.
Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007:CD001447.
Fagius J. Chronic cryptogenic polyneuropathy. The search for a cause. Acta Neurol Scand. 1983;67:173–80.
Prineas J. Polyneuropathies of undetermined cause. Acta Neurol Scand. 1970;46:1–72.
Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164:1021–5.
Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabet Care. 2003;26:3160–7.
Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabet Care. 2001;24:1448–53.
Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006;63:1075–9.
Centers for Disease Control and Prevention (CDC). The prevalence of diabetes and impaired fasting glucose in adults – United States 1999–2000. MMWR Morb Mortal Wkly Rep. 2003;52:833–7.
Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–31.
Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–11.
Low PA. Symptomatic treatment of painful neuropathy. JAMA. 1998;280:1863–4.
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21.
The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8.
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 Trial. Diabet Care. 2006;29:2365–70.
Tang J, Wingerchuk D, Crum B, Rubin DI, Demaerschalk BM. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007;13:164–7.
Dyck PJ, Karnes JL, O’Brien PC, Litchy WJ, Low PA, Melton 3rd LJ. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164–70.
Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med. 1991;325:1487–98.
Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin. 1997;15:615–48.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:403–7.
Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705–13.
Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337–45.
Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112:727–47.
Mendell JR, Sahenk Z, Gales T, et al. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol. 1991;48:1229–34.
Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70:418–24.
Dahlbom K, Lindberg C, Oldfors A. Inclusion body myositis: morphological clues to correct diagnosis. Neuromuscul Disord. 2002;12:853–7.
Choy EHS, Hoogendijk JE, Lecky B, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2005;3:CD003643. doi:10.1002/14651858.CD003643.pub2.
Griggs RC. The current status of treatment for inclusion-body myositis. Neurology. 2006;66:S30–2.
Brannagan 3rd TH. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve. 2009;39:563–78.
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as a treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
Dalakas MC, Sonies S, Dambrosia JM, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6.
Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22–8.
Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–7.
Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47:1233–8.
Poulas K, Tsibri E, Kokla A, Papanastasiou D, Tsouloufis T, Marinou M, et al. Epidemiology of seropositive myasthenia gravis in Greece. J Neurol Neurosurg Psych. 2001;71:353–6.
Phillips LH. The epidemiology of Myasthenia Gravis. Ann NY Acad Sci. 2003;998:407–12.
Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36:651–8.
Husain AM, Massey JM, Howard JF, Sanders DB. Acetylcholine receptor antibody measurements in acquired myasthenia gravis. Ann NY Acad Sci. 1998;841:471–4.
Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve. 1992;15:720–4.
Sanders DB, Howard JF, Johns TR. Single-fiber electromyography in myasthenia gravis. Neurology. 1979;29:68–76.
Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol. 2000;111:1203–7.
Farrugia ME, Weir AI, Cleary M, Cooper S, Metcalfe R, Mallik A. Concentric and single fiber needle electrodes yield comparable jitter results in myasthenia gravis. Muscle Nerve. 2009;39(5):579–85.
Benatar M, Hammad M, Doss-Riney H. Concentric-needle single-fiber electromyography for the diagnosis of myasthenia gravis. Muscle Nerve. 2006;34(2):163–8.
Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, et al. An international phase II randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71:400–6.
Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394–9.
Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55:7–15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Crum, B.A., Rubin, D.I., Dimberg, E.L., Goodman, B.P. (2012). Neuromuscular Disorders. In: Burneo, J., Demaerschalk, B., Jenkins, M. (eds) Neurology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-88555-1_9
Download citation
DOI: https://doi.org/10.1007/978-0-387-88555-1_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-88554-4
Online ISBN: 978-0-387-88555-1
eBook Packages: MedicineMedicine (R0)